| Summary: | Introduction. Glioblastoma (GBM) is one of the most malignant tumors. Currently, treatment options for GBM are limited, and patient survival rates over the past decades have not changed significantly.The objective of the study was a comparative study of the expression of proteins Prox1, CD38, and CD133 in GBM in contact (VSVZ+) and not in contact with the ventricular-subventricular zone (VSVZ–).Methods and materials. Immunohistochemical study with antibodies to Prox1, Ki-67, CD38, CD133 and morphometric analysis of GBM fragments of 10 patients of VSVZ + and 8 patients of VSVZ-.Results. The median of the number of CD133+ cells in VSVZ+ and VSVZ-GBM was 34.5 % and 10 %, respectively. CD38+ cells were found in all of the VSVZ+ GBM and only in one of the VSVZ– GBM. PROX1 was expressed in 34.6 % of VSBZ– GBM cells and in 79 % of VSVZ+ GBM cells. The median life expectancy was statistically significantly greater in the GBM VSVZ– group than in the GBM VSVZ+ group (6 versus 4 months). Direct correlations were found between the number of CD38+ and CD133+ cells (r=0.596), between tumor localization and the number of CD133+ cells (r=0.760), inverse correlations between life expectancy and tumor localization (r=–0.607), and the number of CD38+ (r=–0.755) and CD133+ cells (r=–0.630). Regression analysis showed that the number of CD133+ cells was associated with a lifespan of linear function.Conclusions.VSVZ+ GBM have more CD133+ and CD38+ cells and have a lower median survival compared to VSVZ– GBM.
|
|---|
